Cervi-Xpectra System (CXS)

Description

The Cervi-Xpectra System (CXS) is an innovation designed to address the challenges of cervical cancer screening. By leveraging Electrical Impedance Spectroscopy (EIS), this device provides a non-invasive, rapid, and cost-effective diagnostic solution. Unlike traditional methods such as Pap smears and HPV testing, which are time-consuming, invasive, and reliant on laboratory processing, CXS delivers real-time results directly during clinical assessments. This eliminates delays in diagnosis and treatment, streamlining the decision-making process for healthcare providers.

Special Applications

CXS is particularly beneficial for early detection of cervical abnormalities, high-risk patients with a history of HPV infection, and in resource-limited settings where traditional diagnostic infrastructure is often unavailable. This innovative technology has the potential to transform cervical cancer care, ensuring timely diagnosis and significantly improving patient outcomes.

Technology

The CXS leverages Electrical Impedance Spectroscopy, a cutting-edge technique that measures the electrical properties of biological tissues across a range of frequencies. Each type of tissue exhibits unique impedance characteristics based on its biological properties, including cell density, blood flow, water content, and extracellular matrix composition. These factors vary betwee healthy and abnormal tissues, making impedance an excellent diagnostic parameter.

The CXS probe features four metal electrodes strategically positioned for precise data collection. The system applies a electrical signal within a frequency range of 500 Hz to 500 kHz at an amplitude of 0.4 volts. The impedance magnitude and phase are measured using a hig precision electronic circuit.

These parameters are critical for differentiating between benign and malignant tissues. The system is calibrated against gold-standard pathology results, ensuring high diagnostic accuracy.

Features

The CXS device boasts the following features:

Non-Invasive Testing: Utilizes a contact probe for painless and non-invasive tissue evaluation

during routine examinations.

Real-Time Results: Provides immediate diagnostic insights, reducing the time between screening and treatment initiation.

Cost-Effective: Reduces reliance on laboratory infrastructure, offering a more economical diagnostic alternative.

Achievement

Coosa Cancer Care Innovations has made significant strides in advancing cancer diagnosis and treatment through its innovative technologies. The development of groundbreaking devices such as the Cervix Tumor-Impedance Measurement System (CXS) showcases the company’s dedication to improving patient care. With multiple patents granted and recognition in esteemed scientific publications, Coosa continues to set new standards in healthcare innovation. Its contributions have been acknowledged by medical professionals and institutions worldwide, reinforcing its reputation as a leader in the fight against cancer.

Reviews (0)

Reviews

There are no reviews yet.

Be the first to review “Cervi-Xpectra System (CXS)”

1.What is the Cervi-Xpectra System (CXS)?

CXS is an advanced diagnostic device that uses Electrical Impedance Spectroscopy (EIS) to assess cervical tissue non-invasively. It provides real-time results to aid in the early detection of cervical abnormalities.

2.How does CXS work?

CXS measures the electrical impedance of cervical tissue to identify abnormalities. The device is non-invasive and provides immediate insights into tissue pathology during clinical evaluations.

3.What are the advantages of CXS compared to traditional screening methods?

CXS is non-invasive, delivers instant results, eliminates the need for laboratory processing, and is cost-effective. It is particularly beneficial for resource-limited settings and patients who require immediate diagnosis.

4.Who can benefit from CXS?

CXS is ideal for women at risk of cervical cancer, including those with a history of HPV infection, asymptomatic individuals requiring early detection, and patients in underserved areas with limited access to traditional screening tools.

5.Is CXS safe?

Yes, CXS is completely safe. It is a non-invasive procedure that does not require biopsies or other invasive methods, ensuring patient comfort and safety during use.

6.Can CXS replace Pap smears and HPV testing?

CXS complements traditional screening methods by providing rapid, real-time results. While it enhances the diagnostic process, it may not entirely replace established methods in all clinical settings.

7.Where can CXS be used?

CXS is suitable for hospitals, clinics, and mobile healthcare units. Its portability and ease of use make it especially effective in remote and resource-limited areas.

8.How can healthcare providers integrate CXS into their practice?

CXS is designed to seamlessly integrate into clinical workflows, enabling immediate assessment of cervical tissue during routine examinations. Training and support are provided to ensure efficient implementation and use.